The CPROBE study, which was an individual site-specific multi-center IRB-approved longitudinal cohort study, transitioned into a Multi-Site Single IRB record study in 2020, per NIH mandate. To address this, University of Michigan IRBMED served as the IRB of record for the multiple sites. However, after COVID, sites were unwilling to continue to enroll and follow additional participants, so the only remaining active site is the University of Michigan, Ann Arbor. This study is currently operating under the IRB study number HUM00178688.
